Imunon (NASDAQ:IMNN) Releases Quarterly Earnings Results, Beats Estimates By $0.24 EPS

Posted by James Conley on Mar 31st, 2026

Imunon (NASDAQ:IMNN – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($1.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.24, FiscalAI reports.

Imunon Price Performance

Shares of IMNN stock opened at $2.88 on Tuesday. The stock’s fifty day moving average price is $3.20 and its 200 day moving average price is $3.93. Imunon has a 1-year low of $2.52 and a 1-year high of $41.22. The company has a market cap of $8.84 million, a price-to-earnings ratio of -0.30 and a beta of 2.06.

Hedge Funds Weigh In On Imunon

A hedge fund recently bought a new stake in Imunon stock. Armistice Capital LLC bought a new position in shares of Imunon, Inc. (NASDAQ:IMNN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned 8.69% of Imunon as of its most recent SEC filing. 4.47% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on IMNN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Thursday, January 22nd. reaffirmed a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $255.00.

Check Out Our Latest Analysis on Imunon

Imunon Company Profile

(Get Free Report)

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.